Hyundai Bio Receives IRB Approval for Phase 2 Clinical Trial of Oral COVID-19 Treatment 'CP-COV03'
[Asia Economy Reporter Lee Chun-hee] Hyundai Bio announced on the 5th that the phase 2 clinical trial plan for 'CP-COV03,' an oral antiviral drug for COVID-19 under development, received approval on the 4th from the Institutional Review Board (IRB) of Bestian Hospital, the clinical trial institution.
Hot Picks Today
!["Stock Set to Double: This Company Smiles Every Time a Data Center Is Built [Click e-Stock]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026050416112750184_1777878687.jpg)
"Stock Set to Double: This Company Smiles Every...
- "Is Yours Just Gathering Dust at Home? Millennials & Gen Z Rediscover Digicams O...
- "Continuous Groundwater Pumping Causes Mexico City to Sink 24cm Annually... 'Gia...
- "I Take Full Responsibility"... Seongjae Ahn Issues Direct Apology for 'Wine Swi...
- “She Shouted, ‘The Rope Isn’t Tied!’... Chinese Woman Falls from 168m Cliff ...
A Hyundai Bio official stated, "In cooperation with the clinical contract research organization DTNCRO, we will recruit patients to participate in the clinical trial and proceed with the medication process as quickly as possible."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
